Risk Facotors in Young CHD Patients

Risk Factors Investigation in Young Patients With Coronary Artery Disease and Their Clinical Follow-up

Coronary heart disease (CHD) is the leading global cause of human death. Over the past decade, level of overall diagnosis and treatment of CHD has been greatly improved due to the progression of clinical research and development of technical means and the mortality of CHD has decreased by nearly 50% in western countries [1]. However, there are surveys shows that with the improvement of living standards and changes in lifestyle, the incidence of CHD is still rising in China and other developing countries, and the prevalence trend is obvious younger [2]. The so-called young CHD, generally refers to the age at onset of CHD is less than or equal to 45 years. Compared with other age-group CHD, young CHD has the following characteristics: 1. Genetic factors have a stronger effect at younger onset ages, and incidence with obvious familial aggregation[3]; 2 Often with the onset of acute coronary syndrome, presumably may be associated with strong inflammation of the lesion; 3. Two extremes often exists in coronary lesions: mild or no atherosclerosis and severe triple-vessel disease; 4 Rapid progression of atherosclerotic lesions, stent restenosis in the same site repeated after interventional treatment, rapid progress of lesion in non-intervention site;5 Surgical mortality is low in regardless of interventional therapy or bypass surgery, but the rate of revascularization is significantly higher in following 10 years.

Study Overview

• Status: Unknown
• Conditions: Risk Factor, Cardiovascular, Young CHD Patients
• Intervention / Treatment: Other

Detailed Description

Study method

• Recruited the patients meet the inclusion criteria since March 2016, collected the information of the change of risk factors, angina in pre-operation, mode of onset, characteristics of coronary artery, morbility of treatment,clinical follow-up; ② Collect the following information in clinical cases: gender, age, history of hypertension, history of diabetes, cholesterol level, triglyceride level, sedentary, body index, family history of CHD, genotype of ALDH2 and MTHFR, history of myocardial infarction, coronary artery lesions and operation situation; ③ The follow-up was performed through clinic and telephone every half or one year. The details include whether recurrence of angina, the main symptom, the cause of attack, lasting time, the efficacy of taking nitroglycerin, whether performed electrocardiography examination, whether occurred myocardial infarction and the attack site. whether performed interventional therapy and CABG surgery again and the cause of surgery, whether re-examined coronary arteriongraphy, whether death and the cause, and the occurred date in above events; ④ Analysis the pathogenic intensity with each risk factors with other age group CHD.

3.2 Study population 3.2.1 inclusion criteria

Young CHD group:

• Below or equal to 45 years of age;

  ② Patients suffered stable or latent coronary heart disease, unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction diagnosed by coronary angiography or coronary CT scan;

  ③ Signed informed consent form. Non-young CHD group

• Below or equal to 45 years of age;

  ② Patients suffered stable or latent coronary heart disease, unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction diagnosed by Coronary angiography or coronary CT scan;

  ③ Risk factors such as the gender, high cholesterol, high blood pressure, overweight, diabetes, smoking, homocysteine levels matched with inclusion criteria 1 subjects enrolled.

  ④ Signed informed consent form Young non-coronary heart disease

• Below or equal to 45 years of age; ② Patients were confirmed to rule out the stable or latent coronary heart disease, unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction diagnosed by Coronary angiography or coronary CT scan;

  ③ Signed Informed consent form. 3.2.2 Exclusion criteria Exclusion criteria in each group are as follows

• Patients who suffered serious liver and kidney diseases, infections, severe systemic disease such as blood disease and malignant tumor;

  ② Pregnancy or breast-feeding women;

  • Patients who could not timely follow up or refuse to participate in this study. 3.2.3 Exit criteria Subjects were claimed to withdraw informed consent. 3.3 Grouping method and cases number

• Experimental group：1250 samples

  • Positive control group：1250 samples ③ Negative control group：500 samples

• Study Type: Observational
• Enrollment (Anticipated): 1000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

①Below or equal to 45 years of age;

②Patients suffered stable or latent coronary heart disease, unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction diagnosed by coronary angiography or coronary CT scan;

Description

Inclusion Criteria:①Below or equal to 45 years of age;

②Patients suffered stable or latent coronary heart disease, unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction diagnosed by coronary angiography or coronary CT scan

Exclusion Criteria:

• Patients who suffered serious liver and kidney diseases, infections, severe systemic disease such as blood disease and malignant tumor; ②Pregnancy or breast-feeding women; ③Patients who could not timely follow up or refuse to participate in this study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
CHD Patients; coronary angioplasty confirmed coronary heart disease.
non-CHD patients; coronary angioplasty confirmed no coronary heart disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
heart failure	LVEF less than 40%	12 months

Collaborators and Investigators

• Sponsor: Shanghai Zhongshan Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): February 1, 2017
• Primary Completion (Anticipated): January 31, 2020
• Study Completion (Anticipated): July 31, 2020

Study Registration Dates

• First Submitted: February 1, 2017
• First Submitted That Met QC Criteria: February 1, 2017
• First Posted (Estimate): February 2, 2017

Study Record Updates

• Last Update Posted (Estimate): February 2, 2017
• Last Update Submitted That Met QC Criteria: February 1, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Other Study ID Numbers: 2016-02-25-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: laboratory test

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No